Robert Ennis


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Robert Ennis regularly represents life sciences companies, health care organizations, and other businesses in connection with regulatory, enforcement, and business matters. He frequently counsels clients with respect to internal and government investigations and inquiries, including investigations by the US Department of Justice, the Federal Trade Commission, the New York Attorney General, and the Securities and Exchange Commission. He also handles proactive internal reviews and risk-assessments, advises on federal and state regulations, and counsels life sciences clients with respect to anti-corruption laws in the U.S. and internationally.

Robert believes in providing his clients with practical solutions that effectively manage legal risk, while keeping in mind their wider business strategy. He has experience in acquisitions, joint ventures, strategic alliances and collaborations, including cross-border transactions, for both private equity and corporate clients.  He frequently provides advice in connection with corporate transactions that implicate health care laws and regulations, including the Food, Drug and Cosmetics Act, Anti-Kickback Statute, False Claims Act, HIPAA, Foreign Corrupt Practices Act, as well as fee-splitting and corporate practice of medicine laws, Medicare/Medicaid laws, and related industry codes and standards. 



Bar Admissions

  • California
  • New York

Court Admissions

  • U.S. District Court, Central District of California


  • The University of Chicago Law School, LL.M: Berthold Harris Scholar
  • University College Dublin Law School, B.C.L. (J.D.): summa cum laude; Articles Editor, University College Dublin Law Review; James C. Brady Memorial Gold Medal Winner

Professional Activities


  • Honorable Richard D. Cudahy, United States Court of Appeals for the Seventh Circuit
  • Honorable Manuel Real and Honorable Philip Gutierrez, United States District Court for the Central District of California
  • Honorable Mary Ann Murphy, Los Angeles Superior Court


  • “Tipping Liability in the Wake of ‘Martoma II’,”New York Law Journal (September 2018)
  • Competing Priorities in Antitrust Enforcement: Europe and The New Economy, 11 University College Dublin Law Review 47 (2011)


  • “Can The Government “Do No Wrong?”: The Ever Expanding Doctrine Of Governmental Immunity In Illinois,” 14 ITLA Trial Journal 2 (Summer, 2012)

Former Vice President

  • Irish-American Bar Association of Los Angeles


  • Irish-American Bar Association of New York
  • Counseling a Chinese biotechnology company in connection with a proposed merger.
  • Advising a U.S. medical device manufacturer in connection with a collaboration agreement with a leading U.K. university.
  • Representing a global medical device company in consumer-fraud investigations by multiple state attorneys general.
  • Represented a leading pharmaceutical company in connection with a major SEC investigation into suspected cyber-intrusion and data breach.
  • Advised a health IT company in its contractual negotiations with several pharmaceutical manufacturers and specialty pharmacies. 
  • Defended a leading reproductive health care organization in connection with multiple congressional investigations.
  • Represented a Chinese medical device company in connection with multiple acquisitions of U.S. medical device manufacturers.
  • Represented Samsung Electronics Co. Ltd. in its acquisition of NeuroLogica Corp., a leading designer, developer and manufacturer of computed tomography (CT) machines, including its world-class portable CT scanners.